论文信息 - Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines - 字舞流文

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Paul J. Birrell | K. Lythgoe | D. Bonsall | G. Screaton | T. Peto | D. Crook | B. Marsden | H. Fryer | T. Golubchik | D. Eyre | N. Stoesser | D. Conway | M. Macleod | A. Walker | P. Birrell | P. Matthews | W. Dejnirattisai | R. Cornall | J. Mongkolsapaya | Katie Allison | J. Robotham | J. Farrar | K. Pouwels | T. House | A. Howarth | S. Hoosdally | Tim Evans | K. Paddon | I. Diamond | E. Rourke | R. Studley | K. Chau | J. Kavanagh | Jia Wei | H. Jordan | P. Brereton | Tim Sheppard | S. Hatch | D. Ayoubkhani | J. Hay | T. James | S. Cox | J. Bell | E. Jones | E. Pritchard | K. Vihta | J. Newton | G. Doherty | Daniela Ebner | Thomas Christott | H. VanSteenhouse | Russell C. Black | M. Crees | Antonio Felton | Joel J. Jones | L. Lloyd | Esther Sutherland | Sarah Cameron | Christy A. Cunningham | Magda Wolna | D. Cook | L. M. Ferreira | Jessica L. Lee | D. Stuart | Sophie Davis | D. Moody | Leigh Curry | Tina Daniel Russell Antonio Megan Joel Lina Esther Emma Thomas Ayoubkhani Black Felton Crees Jones L | Tina Thomas | Phoebe Tamblin-Hopper | Rachael Brown | Graham Athey | Ian Jarvis | Anna Godsmark | George Morris | Bobby Mallick | Phil Eeles | S. White | Lisa Bloemberg | Anouska Pandya | Margaret Macleod | Duncan Cook | Tanya Golubchik

[1] T. Peto,et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants , 2022, The New England journal of medicine.

[2] Y. Kreiss,et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.

[3] H. Whitaker,et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England , 2021, Nature Communications.

[4] H. Mitsuya,et al. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals , 2021, Scientific Reports.

[5] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[6] A. Milstone,et al. Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. , 2021, JAMA.

[7] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.

[8] I. Diamond,et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.

[9] Y. Kreiss,et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[10] Rosalind J Wright,et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine , 2021, Cell.

[11] O. A. Ogun,et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[12] T. Pastinen,et al. Prior infection and age impacts antibody persistence after SARS-CoV-2 mRNA vaccine , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13] M. Drayson,et al. Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response , 2021, BMJ Open Respiratory Research.

[14] P. Tighe,et al. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection , 2021, Science Translational Medicine.

[15] J. Tregoning,et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[16] V. Libri,et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[17] M. Zazzi,et al. The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects , 2021, Infection.

[18] H. Rangel,et al. Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose , 2021, International Journal of Infectious Diseases.

[19] M. Lipsitch,et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[20] D. Stuart,et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom , 2021, Nature Microbiology.

[21] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[22] S. Safiri,et al. Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies , 2021, Reviews in medical virology.

[23] C. Donnelly,et al. Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study , 2021, medRxiv.

[24] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[25] Paul J. Birrell,et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.

[26] A. Marchant,et al. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans , 2021, Nature Reviews Immunology.

[27] P. Rodari,et al. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study , 2021, Clinical Microbiology and Infection.

[28] J. Hepojoki,et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants , 2021, Nature Communications.

[29] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[30] J. Farrar,et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom , 2021, Nature Medicine.

[31] A. Sheikh,et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.

[32] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[33] P. Moss,et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people , 2021, medRxiv.

[34] A. Casuccio,et al. Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients , 2021, Vaccines.

[35] M. Dimopoulos,et al. Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine , 2021, American journal of hematology.

[36] J. V. Van Eyk,et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Medicine.

[37] V. Simon,et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[38] D. Stuart,et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera , 2021, Cell.

[39] D. Stuart,et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain , 2021, Cell.

[40] G. Rodger,et al. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[41] J. Dogné,et al. Antibody titres decline 3-month post-vaccination with BNT162b2 , 2021, Emerging microbes & infections.

[42] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[43] M. Drayson,et al. Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response , 2020, medRxiv.

[44] Paul J. Birrell,et al. Community prevalence of SARS-CoV-2 in England during April to September 2020: Results from the ONS Coronavirus Infection Survey , 2020, medRxiv.

[45] G. Rodger,et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.

[46] S. Farhadian,et al. Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.

[47] M. Altfeld,et al. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions , 2020, Immunity.

[48] R. Owens,et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, Cell Host & Microbe.

[49] Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.

[50] C. Y. Li,et al. A review of the healthy worker effect in occupational epidemiology. , 1999, Occupational medicine.